Target intelligence / Profile preview

RNA, U6 small nuclear 263, pseudogene (RNU6-263P)

Target: RNU6-263P
Molecular classification: Other (non-coding RNA pseudogene), Not classified as receptor, ion channel, enzyme, transporter, transcription factor, or histone modification

Overview

RNU6-263P is a human pseudogene corresponding to the U6 small nuclear RNA gene family. The U6 small nuclear RNA is an essential non-coding RNA that forms part of the core spliceosomal machinery for pre-mRNA splicing in the nucleus, a process widely conserved in eukaryotic organisms. However, RNU6-263P itself is classified as a pseudogene, indicating it is a genomic sequence similar to functional U6 snRNA genes but is not transcribed into a functional RNA and does not participate directly in cellular or disease processes[1][4].

Other names: RNU6-263PRNA, U6 small nuclear 263, pseudogene

Mechanism of action

None

Biological functions

None (for the pseudogene itself); true U6 snRNA, which this pseudogene is related to, is involved in pre-mRNA splicing in the nucleus[2][3]. Pseudogene sequences typically lack significant biological functions.

Disease associations

None (for the pseudogene itself). Functional U6 snRNA is essential for cell viability and gene expression; alterations in U6 snRNA expression may be associated with some cancer states and other diseases, but pseudogenes are not well established in disease etiology or as therapeutic targets[5].

Safety considerations

None. Pseudogenes do not encode functional proteins or RNAs and thus are not therapeutically actionable or associated with notable safety challenges.

Biomarkers

None for the pseudogene. U6 snRNA is sometimes used as a normalization control in RNA-based assays (e.g., qPCR), but not its pseudogenes[5].

Beyond the preview

Go deeper on RNA, U6 small nuclear 263, pseudogene (RNU6-263P).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RNA, U6 small nuclear 263, pseudogene (RNU6-263P).

Explore the full profile